Tianjin Pharma Approves Funds for Cash Flow

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, has announced the Board’s approval for the temporary use of RMB230 million from the net proceeds of a previous A-share placement to support the company’s cash flow for up to 12 months. The funds were part of the RMB814,340,000.00 net proceeds raised from the 2015 share issuance after deducting expenses. This move is part of ongoing financial strategies to ensure the company maintains operational liquidity.

For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.